Hyundai Bioland
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Hyundai Bioland makes ingredients derived from natural sources, such as hyaluronic acid, beta-glucan, and plant-based collagen, used in cosmetics, health supplements, pharmaceutical actives, and medical devices including dental bone-regeneration materials.
It supplies these ingredients to cosmetics companies, pharmaceutical firms, and healthcare brands globally, and also distributes premium international health supplement brands exclusively within South Korea. Listed on KOSDAQ, Korea's tech and small-cap board, its cosmetics ingredient business accounts for the largest share of revenue, with brand distribution and medical devices making up most of the remainder.
Summary is AI-generated and may contain errors · figures from DART filings
The company exclusively distributes Nestlé Health Science brands, including Solgar and Vital Proteins, in South Korea, operating dedicated retail shops under that partnership.
Hyundai Bioland in five facts
What does Hyundai Bioland do?
Hyundai Bioland makes ingredients derived from natural sources, such as hyaluronic acid, beta-glucan, and plant-based collagen, used in cosmetics, health supplements, pharmaceutical actives, and medical devices including dental bone-regeneration materials.
Where is Hyundai Bioland listed and in which sector?
Hyundai Bioland (Korean name: 현대바이오랜드) trades under KRX code 052260 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Materials sector, Chemicals.
How large is Hyundai Bioland?
Its market capitalisation was US$100.5M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Hyundai Bioland's latest annual revenue and operating profit?
For fiscal year 2025, Hyundai Bioland reported revenue of US$98.5M, operating profit of US$9.6M and net income of US$190.7K, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 9.2% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Operating results (consolidated) (preliminary) (fair disclosure)
Hyundai Bioland filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$28.2M (+16.4% year on year), operating profit of US$4.93M (+27.9% year on year) and net income of US$4.17M (+17% year on year).
Earnings · Aug 3 - Operating results (consolidated) (preliminary) (fair disclosure)
Hyundai Bioland filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$25.9M (+13.5% year on year), operating profit of US$3.52M (+4.4% year on year) and net income of US$3.54M (from a loss a year earlier).
Earnings · Apr 30 - Cash/in-kind dividend decision
Hyundai Bioland declared a cash dividend of US$0.05 per share.
Dividend · Feb 5 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Hyundai Bioland reported consolidated results for FY2025: revenue of US$89.4M (+9.2% year on year), operating profit of US$8.71M (−22.3% year on year) and net income of US$173K (−95.6% year on year).
Earnings · Feb 5